Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
Epistemonikos ID: e7dd611864ff774bdf879011e06c2f0e03ea449e
First added on: May 11, 2024